retatrutide type 2 diabetes phase 2 trial hba1c Retatrutide: A Triple Agonist Shaping the Future of Metabolic Care Triple Agonism Based Therapies for

Individuals with obesity and type 2 diabetes have higher baseline rates of depression and mental health conditions compared with the general population, making it difficult to determine whether reported symptoms represent medication effects or underlying psychiatric comorbidity

Starting protective strategies before shedding occurs can reduce risk by up to 80% in some cases

[Google Scholar] [2].Wild RA, Carmina E, Diamanti-Kandarakis E, et al

Retatrutide, which has not yet completed clinical trials, is an experimental injection developed by the US drugmaker Eli Lilly that targets three gut hormones: GLP-1, GIP and glucagon